NVO Projected Dividend Yield
ADR/Novo-Nordisk AS ( NYSE : NVO )Novo Nordisk A/S is a global healthcare company engaged in diabetes care. Co. is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. Co. operates through two business segments: diabetes and obesity care, and biopharmaceuticals. Co.'s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. Co.'s biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. Co. also offers Saxenda product to treat obesity. 29 YEAR PERFORMANCE RESULTS |
|
NVO Dividend History Detail NVO Dividend News NVO Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
2026 |
N/A |
Mar 30, 2026 |
Mar 30, 2026 |
Apr 08, 2026 |
0.8737 |
2026 Total: |
0.8737 |
||||
2025 |
N/A |
Aug 18, 2025 |
Aug 18, 2025 |
Aug 26, 2025 |
0.4116 |
2025 |
N/A |
Mar 31, 2025 |
Mar 31, 2025 |
Apr 08, 2025 |
0.8191 |
2025 Total: |
1.2306 |
||||
2024 |
N/A |
Aug 16, 2024 |
Aug 16, 2024 |
Aug 26, 2024 |
0.3623 |
2024 |
N/A |
Mar 22, 2024 |
Mar 25, 2024 |
Apr 02, 2024 |
0.6634 |
2024 Total: |
1.0258 |
||||
2023 |
N/A |
Aug 18, 2023 |
Aug 21, 2023 |
Aug 29, 2023 |
0.3124 |
2023 |
N/A |
Mar 24, 2023 |
Mar 27, 2023 |
Apr 04, 2023 |
0.4234 |
2023 Total: |
0.7358 |
||||
2022 |
N/A |
Aug 12, 2022 |
Aug 15, 2022 |
Aug 23, 2022 |
0.2034 |
2022 |
N/A |
Mar 25, 2022 |
Mar 28, 2022 |
Apr 05, 2022 |
0.3657 |
2022 Total: |
0.5691 |
||||
2021 |
N/A |
Aug 16, 2021 |
Aug 17, 2021 |
Aug 25, 2021 |
0.1934 |
2021 |
N/A |
Mar 26, 2021 |
Mar 29, 2021 |
Apr 07, 2021 |
0.3316 |
2021 Total: |
0.5249 |


